Sai Parenteral'S has secured a confirmed Rs 204 crore work order for the renewal of an OTC medicines supply agreement with one of Australia's leading pharmacy chains. The contract spans three years and covers manufacturing, sourcing, regulatory compliance, and nationwide distribution.

WHAT HAPPENED

Sai Parenteral received a confirmed work order valued at Rs 204 crore from one of Australia's leading pharmacy chains. This is a renewal of the existing OTC Medicines Supply Agreement, featuring an expanded product portfolio. The contract term is three years, covering end-to-end value chain management including manufacturing, TGA registrations, warehousing, quality assurance, and distribution. The filing was disclosed to exchanges on 25 August 2026.

ORDER IN FINANCIAL CONTEXT

The Rs 204 crore order value is approximately 1.52 times the company's average quarterly revenue of Rs 134.35 crore. When added to previous wins, the total disclosed order book stands at Rs 5613 crore (sum of the 7 orders disclosed across the last 3 fiscal quarters shown in the table below). This backlog represents 41.78 quarters of average quarterly revenue, indicating a substantial pipeline relative to current sales scale. The book-to-bill ratio is extremely elevated, suggesting that execution capacity and working capital deployment will be the primary constraints on near-term revenue realization rather than order acquisition.

COMPANY ORDER TRACK RECORD

Order inflow velocity has remained stable at high levels over the last two reported quarters. Q2FY27 saw Rs 2804.00 crore in inflows, closely mirroring the Rs 2809.00 crore recorded in Q1FY27. The current Rs 204 crore order is smaller than the mega-contracts (Rs 1300 crore each) signed earlier in the period but consistent with the company's strategy of securing multiple large-scale agreements with key international partners. The client base remains heavily concentrated on Australian pharmacy networks.

EXECUTION AND REVENUE QUALITY

The company reported consolidated revenue of Rs 182.40 crore in Q1FY27, up from Rs 99.30 crore in Q3FY26, though down from Rs 200.80 crore in Q4FY26. Net profit stood at Rs 7.90 crore in Q1FY27, recovering from a net loss of Rs 6.70 crore in Q3FY26. Operating profit margin (OPM) improved to 13.16% in Q1FY27 from negative 3.70% in Q3FY26, but remained slightly below the 13.18% recorded in Q4FY26. This volatility suggests ongoing margin pressure or one-off costs affecting profitability despite strong top-line growth.

REVENUE GROWTH - ORDER WINS TRANSLATING TO REVENUE

As Sai Parenteral has sustained order wins, with significant inflows in recent quarters, its annual revenue has grown from Rs 163.70 crore in FY25 to Rs 381.00 crore in FY26, representing a YoY growth of +132.7% based on the latest annual data. This sharp acceleration in revenue aligns with the ramp-up of large international contracts, although net profit declined by 51.4% in the same period, highlighting a divergence between top-line expansion and bottom-line retention.

WORKING CAPITAL AND EXECUTION CAPACITY

The company maintains a current ratio of 1.44x, providing adequate short-term liquidity to manage operations. Total Liabilities/Equity stands at 1.90x, which includes trade payables and other non-debt liabilities alongside any borrowings. Operating cashflow improved significantly to Rs 93.10 crore in FY26 from Rs 33.20 crore in FY25, while free cashflow was positive at Rs 27.60 crore. This positive cash conversion indicates that the company is effectively collecting receivables and managing working capital cycles, which is critical for funding the execution of its large order book without excessive external financing.

WHAT TO WATCH

• Execution rate: Monitor whether quarterly revenue can sustainably scale to match the Rs 5613 crore backlog without diluting margins further.
• Margin trajectory: Watch for stabilization of OPM above 13% as new contracts execute, given the recent volatility including a loss-making quarter.
• Client concentration: A significant portion of the disclosed order book comes from Australian pharmacy networks; any disruption in these relationships would impact the backlog materially.
• Working capital efficiency: Ensure that the rapid revenue growth does not stretch receivables days, potentially turning positive operating cashflows negative.

KEY OBSERVATIONS

• Margin stress: Net loss of Rs 6.70 crore in Q3FY26; execution stress visible in quarterly data, though recovered in subsequent quarters.
• Valuation check (as of 25 Aug 2026): P/E of 112.6x against ROCE of 28.92%. At the time of this article, valuation was pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
• Backlog signal: Book-to-bill of 41.78x. At this level, execution capacity becomes the binding constraint.
• Promoter holding: Moved from 61.23% to 51.16% in Q1FY27, a 10.07 pp change.

Sai Parenterals Limited will host a group meeting for analysts and institutional investors on Monday, August 31, 2026. The physical event will take place in Mumbai starting at 10:00 am.

The meeting is hosted by Strategic Growth Advisors Pvt. Ltd. Management officials will participate in the session to discuss publicly available information. The company confirmed that no unpublished price-sensitive information will be shared during the interaction.

This disclosure is made pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.

The schedule remains subject to change due to exigencies on the part of the host or the company.